PharPoint Research joins Medidata's ASPire to Win channel partner program

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that PharPoint Research, Inc., a North Carolina-based drug development service company, has joined Medidata's ASPire to Win^® channel partner program, bringing the program's partner count to 30 organizations. With this partnership, PharPoint will be able to offer the Medidata Rave^® electronic data capture (EDC) and clinical data management (CDM) solution to its clinical research customers.

“PharPoint has proven its ability to deliver a range of critical tools and services to pharma and biotech sponsors looking to increase clinical research efficiency”

With extensive experience serving pharmaceutical and biotechnology companies of all sizes in more than 30 countries on six continents, PharPoint's specialties include strategic development consulting, data management and statistical services. Through Medidata's CRO partner program, PharPoint will further add to its expertise in managing EDC-driven clinical programs.

PharPoint's decision to offer Medidata Rave services was based on the solution's widespread acceptance and usability among clinical research sponsors and global investigator sites. The PharPoint team expects its customers to benefit from Rave's ability to eliminate tedious paper processes and CRF storage at clinical sites, enable proactive data management and streamline clinical monitoring processes. PharPoint also values Medidata Rave's standards-based architecture and robust integration tools, including Rave Web Services, which support quick integrations with other systems for data sharing in an eClinical environment.

"Medidata Rave offers critical functionality and tools to power researchers to conduct more efficient clinical studies, with the ultimate goal of delivering life-saving treatments to patients much faster," said Audra McRae, chief operating officer, PharPoint. "Partnering with Medidata enables us to combine a leading EDC system with PharPoint's experienced staff to offer our clients both quality systems and excellent service."

Over the next year, PharPoint expects to implement Medidata Rave in a range of multinational Phase II and III trials as well as Late Phase studies.

"PharPoint has proven its ability to deliver a range of critical tools and services to pharma and biotech sponsors looking to increase clinical research efficiency," said Graham Bunn, vice president, global partnerships, Medidata Solutions. "The ASPire to Win program will enable PharPoint to quickly and easily offer Medidata Rave services and fulfill increasing customer demand for an industry-leading EDC/CDM solution."

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, the program has grown to include 30 partners, ranging from smaller clinical consultancies to large, global CROs.